Advertisement

Topics

Sobi Company Profile

06:10 EDT 26th June 2019 | BioPortfolio

Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi’s mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. Sobi also markets a portfolio of specialty and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies.


News Articles [51 Associated News Articles listed on BioPortfolio]

Sobi buys AstraZeneca's RSV virus drug for $1.5bn

Sobi has completed the acquisition of AstraZeneca’s Synagis (palivizumab) for $1.5 billion in cash and shares, plus certain conditional payments. As part of the deal, first announced in August, Sob...

Sobi Acquires Novimmune Rare Disease Drug Emapalumab and Related Assets

STOCKHOLM, June 12, 2019 /PRNewswire/ — Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) has signed an agreement to acquire, from Novimmune’s shareholders, a newly established compa...

Sobi acquires Synagis US rights from AstraZeneca

The deal also provides Sobi with the right to participate in payments from the US profits or losses for new medicine MEDI8897 in development for RSV-induced LRTI As The post Sobi acquires Synagis US ...

Sobi to acquire emapalumab drug from Novimmune

Swedish Orphan Biovitrum (Sobi) has agreed to buy a newly established firm from Novimmune for a consideration of SEK4,897m ($517.9m)....Read More... The post Sobi to acquire emapalumab drug from Novim...

Sobi pays CHF515mm to buy newco housing Gamifant from Novimmune

One year after granting Swedish Orphan Biovitrum AB (Sobi) exclusive global rights to the interferon gamma antagonist emapalumab (which has since been approved as Gamifant), Novimmune SA has now creat...

Sobi acquire Novimmune in deal worth more than £400 million

Swedish rare disease specialist Sobi has agreed to buy Swiss firm Novimmune ion a deal worth more than £400 million. The deal will see Sobi gain access to world class R&D facilities in the area o...

Sobi tar klivet in bland större läkemedelsbolag

Sobi meddelade i mitten av november att man köper rättigheterna till ett läkemedel från Astra- Zeneca med den största marknadsandelen i USA.

Sobi gains exclusive US rights to AZ's Synagis; deal value tops $2.3bn

AstraZeneca PLC sold Swedish Orphan Biovitrum AB (Sobi) exclusive rights to commercialize the respiratory syncytial virus therapy Synagis (palivizumab) in the US. Sobi will also participate in AZ’s ...

Drugs and Medications [3 Associated Drugs and Medications listed on BioPortfolio]

Orfadin [swedish orphan biovitrum ab (publ)]

These highlights do not include all the information needed to use ORFADIN safely and effectively. See full prescribing information for ORFADIN. ORFADIN (nitisinone) capsules, for oral useORFADIN (niti...

Kepivance [swedish orphan biovitrum ab (publ)]

These highlights do not include all the information needed to use Kepivance safely and effectively. See full prescribing information for KEPIVANCE. KEPIVANCE (palifermin) for injection, for intravenou...

Orfadin [swedish orphan biovitrum ab (publ)]

These highlights do not include all the information needed to use ORFADIN safely and effectively. See full prescribing information for ORFADIN. ORFADIN (nitisinone) capsules, for oral useORFADIN (niti...

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [6 Associated Companies listed on BioPortfolio]

Swedish Orphan Biovitrum AB

Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients and their families. Sobi have a diversi...

Sobi

Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi’s mission is to develop and deliver innovative therapies and services to improve the li...

Sobi Inc.

Biogen and Sobi

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare ...

Bioverativ Inc. & Sobi

Bioverativ (NASDAQ: BIVV) is a global biopharmaceutical company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class re...

More Information about "Sobi" on BioPortfolio

We have published hundreds of Sobi news stories on BioPortfolio along with dozens of Sobi Clinical Trials and PubMed Articles about Sobi for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Sobi Companies in our database. You can also find out about relevant Sobi Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...


Corporate Database Quicklinks



Searches Linking to this Company Record